Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-036692
Filing Date
2025-03-10
Accepted
2025-03-10 20:00:05
Documents
1
Period of Report
2025-03-06

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 8518
  Complete submission text file 0000950170-25-036692.txt   10218
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Issuer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 215 FIRST STREET CAMBRIDGE MA 02142
Business Address
Murray Dallan (Reporting) CIK: 0002022303 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-14895 | Film No.: 25725470